A-phase II study of intravenous 6-thioguanine (NSC-752) in multiple myeloma. A Southwest Oncology Group study.
Thirty-three patients with relapsing or refractory multiple myeloma were treated with 6-Thioguanine (6TG) at a dose of 1 g/M2, with therapy given over four hours every three weeks. The major toxicity seen was myelotoxicity; thrombocytopenia was more commonly noted than neutropenia. One patient achieved a PR, two were clinically improved. 6TG in this short infusion schedule proved to be myelotoxic, but demonstrated little activity in previously treated myeloma patients.
Edelstein
M B
MB
Wayne State University Medical Center, Seattle.
Crowley
J J
JJ
Valeriote
F A
FA
Bonnet
J D
JD
Carden
J O
JO
Khanna
R C
RC
Salmon
S E
SE
Ungerleider
J S
JS
D004341:Drug Evaluation; D006801:Humans; D007262:Infusions, Intravenous; D009101:Multiple Myeloma / Q000188:drug therapy*; D013866:Thioguanine / Q000008:administration & dosage / Q000627:therapeutic use* / Q000633:toxicity
D013866:Thioguanine